Pseudomonas aeruginosa is an opportunistic bacterium that can proliferate in the soil, water, and even humans if they are immunologically depressed. During lung infections, P. aeruginosa goes through significant morphological changes turning into the mucoid form after which its eradication becomes almost impossible. Within this chapter, we explore the bioenergetics changes produced within P. aeruginosa during infections in humans and the metabolic pathways that are involved in those changes that lead to chronic infection. 2 transmembrane conductance regulator (CFTR) identified as F508, G542X, G551D, W1282X, R1162X, and N1303K [24, 25]. CF also has co-morbidity such as liver cirrhosis [26] with 18% prevalence [27, 28] of P. aeruginosa infection in this subset.
Introduction
There are many lung pathogens but one of the most studied is Pseudomonas aeruginosa because it cannot be eradicated under certain conditions. As an opportunistic pathogen, its interaction with the host has some particularities that we will explore in this chapter.
The Pseudomonadaceae comprise Gram-negative microorganism, nonsporulated, aerobic strict of wide distribution in the environment from the soil, water, and plants to humans; this is due to their nutritional versatility. Of this vast group, only Pseudomonas cepacia, mallei, and aeruginosa infect humans, of which aeruginosa is the more relevant because it is the most frequent cause of nosocomial infections [1] .
It is often said that Pseudomonas aeruginosa does not infect healthy individuals but there are reports on the contrary, as swimmers otitis [2] . Because it is an opportunist pathogen, it does not need the host for its survival, and it may be lethal after becoming a chronic infection in susceptible patients with cystic fibrosis (CF) [3] [4] [5] , cancer [6-8], hepatic cirrhosis [9] , keratitis [10-13], or spondylodiscitis [14] . This bacterium is most feared by pulmonologist because when acquired by nosocomial patients [15, 16] , it complicates any existing conditions, and when it invades immune-compromised patients, its eradication may become impossible.
Colonization with P. aeruginosa is observed in all stages of chronic obstructive pulmonary disease (COPD), but the prevalence significantly increases with disease severity from 0.7%, in stage 1 of the Global Initiative for Obstructive Lung Disease, to 1.5% for stages 2 and 3 up to 2.6% for stage 4 [17, 18] . This prevalence rises to 8-13% in acute exacerbations of COPD [19] [20] [21] . But still, the main susceptibility for the infection and death by P. aeruginosa [22, 23] are the mutations of the CF [62] . b Relative change of lung cell gene profile after 3 h contact with P. aeruginosa [43] . Data reported by Naughton [62] and Ichikawa et al. [43] . Table 1 . Genetic changes due to host-pathogen interaction quantified by microarrays of mRNA.
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with the upregulation of proteins involved in adherence, lysozyme resistance, and inhibition of the chloride ion channel, and CFTR [63] . P. aeruginosa releases choline from surfactants [81] . In vitro studies utilizing choline, as a carbon and nitrogen source, shows that it produces accumulation of polyphosphates (polyPi), carbohydrates, and LPS accompanied by depletion of phosphate (Pi) and phospholipids (PL); deeply modifying its energetic metabolism, the bacteria save 45% of energy in polyPi [64] (Table 2) .
After the invasion, the bacteria attach to the lung epithelium producing profound metabolic changes, which correlates with morphological changes to the rugose small-colony variant (RSCV) [65] [66] [67] . The transition to the RSCV precedes inactivation of serine hydroxymethyltransferase; this produces accumulation of cyclic diguanylate [68] and nucleotide ppGpp that leads to polyPi accumulation [69] and to alginate production [68, [70] [71] [72] . Table 2 shows that the total content of phosphate is reduced 3 times in choline feed bacteria, although it accumulates Pi in polyPi. The polyPi may be thought as the energetic savings of the bacteria which is done at expenses of phospholipid biosynthesis. This is possible reducing the size of the bacterium [73] and increasing the area/volume ratio that facilitates O 2 exchange for which the bacteria have to compete with the host [74]. The overall bacterial changes save energy accumulating ppGpp, the substrate for polyPi synthesis by polyphosphate kinase, which is also increased [75] . Some of these polyPi are located in the outer membrane where this highly energetic polymer has Pi bonds similar to the ATP and a highly negative charge neutralized by cations such as Ca 2+ and Mg 2+ . Thus, polyPi function as an energy storage, buffer, and ion chelator that may shield the bacterium from environmental changes.
After adhering to the host ciliated epithelial cells, through mucin, the bacterium is enabled to form aggregates, secrete alginate, and modify its LPS [76] ; this is a process regulated by 3,5-cyclic diguanylic acid [68] . The LPS is a macromolecule (C 205 H 366 N 3 O 117 P 5 ) of 4899.956 g/mol that covers the outer membrane extending 40 nm outward. It is released with vesicle-containing enzymes and outer membrane (OM). Its extended formula was determined in 2003 (Figure 1) ; it is anchored to the OM through the lipid A which binds to the 3-deoxy-d-manno-2-octulosonic acid (KDO), the first glycoside of the core oligosaccharide, bound to the distal O antigen, a highly variable region [77, 78] . A metabolic crossroad between the LPS and alginate biosynthesis (Figure 2) is mannose-6-phosphate isomerization to mannose-1-phosphate by phosphomannomutase (Alg C). The glucose-6 phosphate (G6P) can be transformed to G1P to produce LPS or to isomerize mannose-6-phosphate to G1P. Similarly, fructose-6-phosphate (F6P) can be converted to mannose-6-phosphate and then isomerized to mannose-1-phosphate that becomes alginate by d-mannuronate linkage to l-guluronate via a P-1,4 glycosidic bond. Thus, isomerization of mannose 6-phosphate to mannose 1-phosphate by phosphomannomutase, encoded as algC, is common to the biosynthesis of LPS and alginate since mutants in this phosphomannomutase are hindered in their ability to infect in vivo [79] .
Interaction between lung and bacteria
The host-pathogen interaction studied in vivo utilizing LPS in the lung of mice exposed to cigarette smoke model exacerbations of COPD in patients chronically infected with P. aeruginosa. Figure 3 proposes that this extracellular pathogen releases to the medium phospholipase C (PLC) [80] and phosphorylcholine phosphatase (PChP) [81] within vesicles [82] . These vesicles degrade the surfactant, from phosphatidylcholine [85] to phosphoryl-choline and diacylglycerol (DAG) [83] , causing Ca 2+ mediated vaso-constriction [84] . Choline and phosphate (Pi) released by PChP produce airway constriction and inflammation in the lung tissue. Further validation of this host-pathogen interaction is verified by the metabolite variations in a mouse model that uses live bacteria, instead of LPS. Figure 4A shows that phosphatidylcholine and glycine are significantly reduced in the lung upon infection, due to their consumption, while succinate and lactate are significantly accumulated [85] . Variations of choline concentration in the lung are not significant although glycerophosphocholine and glycine are [86, 87] , which are the degradation Host-Pathogen Interaction in the Lung of Patients Infected with Pseudomonas aeruginosa DOI: http://dx.doi.org/10.5772/intechopen.84657 products of choline. This is because P. aeruginosa is capable of releasing choline and converting it to betaine and then to glycine (Figure 4B ) [88] [89] [90] [91] , for osmoprotection [92, 93] from the hyperosmolarity in the CF lung. Glycine also triggers chloride influx, inhibiting the Ca 2+ mobilized by LPS [94] . This is a mechanism of self-preservation because macrophages are activated by LPS but suppressed by free glycine [95] .
The succinate accumulated in the lung after infection [85] , as Krebs cycle metabolite, inhibits histone demethylases, collagen hydrolases, α-ketoglutarate dioxygenases, and the 5-methylcytosine hydroxylase family [96] . In vitro succinate is the favorite carbon source for P. aeruginosa. Its consumption reduces the length of the LPS (Table 3) , increasing the PL and Pi content and preventing the polyPi accumulation ( Table 2) , which is essential to the stress response [64] . The LPS and , mice treated with of LPS (n = 4), smoke exposed (n = 8) and smoke plus 100 ng/weekly of LPS (n = 3) from P. aeruginosa. *P = 0.01 relative to naïve mice, **P = 0.04 relative to naïve mice, ***P = 0.01 relative to smoke exposed, §P = 0.01 relative to naïve mice, †P = 0.05 relative to smoke exposed, ∫P = 0.05 relative to naïve mice, and ‡P = 0.01 relative to smoke exposed. The figure is taken from Grumelli et al. [64] .
PL biosynthesis has a common metabolite, the R-3-hydroxyacyl-ACP that is the substrate for R-3-hydroxyacyl-ACP dehydrase (FabZ) [98] , to synthesize PL, and for LpxA, for LPS synthesis. Thus, the increased content of PL is at the expense of Lipid A from LPS (Figure 5) , as shown in Table 2 .
The LPS of P. aeruginosa stimulates the O 2 uptake from mitochondria [97] producing decoupling of the oxidative phosphorylation, reducing the respiratory rate, which generates stress in the host lung triggering exacerbations [44, 64, 97] . Therefore, succinate accumulation signifies that choline consumption is increasing the adaptation of the bacteria to the lung environment and the transition to the RSVC form, for chronic infection. 
Chronic infection of P. aeruginosa
Upon infection, the host decreases iron levels in the blood [99] ; this iron deficiency regulates a great number of bacterial virulent genes like alginate, the most relevant virulence factor, for P. aeruginosa survival [100] . In the lung, iron deficiency turns on AlgQ, the bacterial biofilm production gene, also known as AlgR2 [101, 102] , under the Pfr A regulation that assists to the formation of two kinds of cytoplasmic aggregates: large vacuole-like bodies and smaller granules containing iron in association with oxygen or phosphate, very likely polyPi [103] . This leads to the RSCV type of P. aeruginosa. Under these conditions, the bacteria secrete alginate, a linear polysaccharide of d-mannuronic acid linked to l-guluronic acid [104] .
The first gene described for the biosynthesis of alginate was the phosphomannose isomerase and GDP-mannose dehydrogenase (AlgD) that catalyze the conversion of GDP-mannose to GDP-mannuronic acid [105] . Upon oxygen limitation, P. aeruginosa utilizes nitrate or arginine as electron acceptors, via the succinylarginine pathway [106, 107] . The AlgD expression is tightly regulated by several environmental sources including nitrogen, O 2 , Pi, NaCl, etc. Although the regulation of AlgD has been extensively studied, it is not completely understood, and eradication of chronic infection greatly depends on control of alginate production.
Several authors have studied the AlgD regulation, Figure 6 shows a 20-years breach in the finding of AlgD regulators. More positive regulators have been identified, such as AlgR that is upregulated by NaCl and also by the nitrogen source [108] . AlgD is also under the same promoter than PLC, which is sensitive to the nitrogen source [109] that regulates the anaerobiosis genes. These genes detect the ratio of glutamine to 2-ketoglutarate, which is dependent on O 2 availability [108, 110] . Another positive regulator of AlgD is AlgU [111] , but the only negative regulator known is the RpoN, a sigma factor, that regulates nitrogen metabolism. RpoN is increased by disruption of pyrimidine synthesis and decreased by the supplementation with uracil, showing that a high level of RpoN, in the RSCV form, may block the alginate biosynthesis [110, 112] .
Studies on the biosynthetic pathway of biofilms show that chelation of iron by lactoferrin destabilizes the bacterial membrane [113] , which combined with xylitol hinders the ability of the bacteria to respond to iron deficiency [101] , showing some promise for CF treatment.
Conclusions
P. aeruginosa is a relevant pathogen given its widespread prevalence across different organs. The latent menace it poses for inpatients is a liability for institutions. For this, and the negative prognosis that P. aeruginosa infections in CF patients has, it is one of the subjects more researched for the last 40 years. The efforts have resulted in understanding the process of invasion, immune response, and bacterial tactics to achieve chronic infection. The complexity of the metabolic changes caused by the contact between the host and the bacteria is so extensive that the selection of variables for in vitro studies is difficult since the production of biofilm by P. aeruginosa seems to be regulated by everything, O 2 , N 2 , Fe 2+ , Pi, and NaCl. This multiregulatory network is still a puzzle to be resolved.
Scientists agree that suppression of alginate production is vital to treat CF patients, but in 40 years of research, little has been achieved in suppressing its production in vivo.
Perspectives
The advancement of techniques with high output data like microarrays, proteomes, and mass spectrometry are closing the breach among the different approaches that have been used to tackle P. aeruginosa infections. For example, mass-spectrometry has verified through metabolite detection the metabolic pathways studied by molecular biologists and enzymologists. The integration of these studies with the physicians is needed to assess the areas that show more promises to control alginate production and P. aeruginosa eradication after it became a chronic infection. © 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
